Cardiology Research and Practice最新文献

{"title":"Bibliometric Analysis of Research Hotspots and Emerging Trends in Mitochondrial DNA and Atherosclerosis (2004-2025).","authors":"Yun Ouyang, Gesheng Wang, Ming Zhang, Puxuan Min, Mengxiong Guo","doi":"10.1155/crp/2121810","DOIUrl":"10.1155/crp/2121810","url":null,"abstract":"<p><strong>Objective: </strong>To explore the research course, hotspots, and development trends of mitochondrial DNA (mtDNA) and atherosclerosis (AS) based on knowledge graph technology, providing references for clinical and basic research in this field.</p><p><strong>Methods: </strong>Publications themed on mtDNA and AS published between 2004 and 2025 were retrieved from the Web of Science Core Collection (WOSCC) database. CiteSpace 6.4. R1 Advanced software was used to construct and visually analyze knowledge graphs of authors, institutions, keywords, etc.</p><p><strong>Results: </strong>A total of 341 publications were included, with the annual publication volume showing an overall upward trend. Research methods for mtDNA and AS are diversifying, with mechanistic investigations showing a trending focus toward specific molecular pathways. A total of 241 authors and 353 publishing institutions were analyzed. Ten keyword clusters were identified, including Cluster #0 oxidative stress, Cluster #1 mitochondrial DNA, Cluster #2 degradation, Cluster #3 atherosclerosis, Cluster #4 hydrogen peroxide, Cluster #5 roles, Cluster #6 MAPK pathway, Cluster #7 epigallocatechin gallate, Cluster #8 mitochondrial DNA copy number, and Cluster #9 vascular disease.</p><p><strong>Conclusion: </strong>Research has evolved from foundational mechanistic studies to a focus on translational and clinical applications. Moving forward, efforts should be intensified to enhance collaboration among research teams and deepen mechanistic investigations, thereby laying a solid foundation for clinical translation.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"2121810"},"PeriodicalIF":2.1,"publicationDate":"2026-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13284486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TAVR vs. SAVR in Patients With Severe Aortic Stenosis and Chronic Kidney Disease Undergoing Dialysis: A Comprehensive Meta-Analysis.","authors":"Maneeth Mylavarapu, Madiha Kiyani, Niharika Tanwar, Meghana Reddy, Israel Garcia, Nithin Karnan, Nidhi Laxminarayan Rao, Lakshmi Sai Meghana Kodali, Nimisha Borra","doi":"10.1155/crp/9451268","DOIUrl":"10.1155/crp/9451268","url":null,"abstract":"<p><strong>Background: </strong>Patients with chronic kidney disease (CKD) undergoing dialysis who also suffer from severe aortic stenosis (AS) present a complex management challenge. Both transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are treatment options, but comparative outcomes in this specific, high-risk population continue to remain unclear.</p><p><strong>Aim: </strong>This study aims to compare TAVR and SAVR postoperative clinical outcomes in patients with severe AS and CKD undergoing dialysis.</p><p><strong>Methods: </strong>According to PRISMA guidelines, a comprehensive search was conducted across various databases such as PubMed, EMBASE, Scopus, and Google Scholar. Original studies that compared the clinical outcomes between TAVR and SAVR in patients with severe AS and CKD undergoing dialysis were included in the study.</p><p><strong>Results: </strong>Ten studies, all retrospective, involving 28,625 (14,625 TAVR and 14,000 SAVR) patients with severe AS and CKD undergoing dialysis who underwent TAVR or SAVR were included in this study. Patients who underwent TAVR had significantly lower odds of in-hospital mortality (OR 0.49; 0.29, 0.84; <i>p</i> = 0.01) and shorter length of stay (LOS) (SMD -2.59; 95% CI -5.04, -0.14; <i>p</i> ≤ 0.04). However, the TAVR group had significantly higher odds of permanent pacemaker implantation (OR 2.25; 95% CI 1.71-2.94; <i>p</i> < 0.00001).</p><p><strong>Conclusion: </strong>In patients with severe AS and CKD undergoing dialysis, TAVR is associated with lower in-hospital mortality and shorter LOS, suggesting a favorable early safety profile and recovery in this population.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"9451268"},"PeriodicalIF":2.1,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13280660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148293208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine Prevents Postoperative Atrial Fibrillation in Cardiac and Thoracic Surgery Patients: Contemporary Evidence From a Meta-Analysis of Randomized Controlled Trials.","authors":"Muhammad Hassan Saeed, Syeda Zaira Haider, Kishan Chand Lohana, Fnu Kashish, Muhammad Ahmed Zaheer, Tayyaba Naseem Abbasi, Safa Mazhar, Jarin Rahman","doi":"10.1155/crp/1851955","DOIUrl":"10.1155/crp/1851955","url":null,"abstract":"<p><strong>Background: </strong>Postoperative atrial fibrillation (POAF) is the most common arrhythmia following cardiac and thoracic surgery. Stems from atrial oxidative stress and pericardial inflammation, POAF is associated with adverse clinical outcomes such as heart failure, stroke, and increased mortality. As an anti-inflammatory agent, colchicine has shown effective POAF risk reduction.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted including randomized controlled trials (RCTs) evaluating colchicine for POAF prevention till september 2025. Data were pooled using random-effects models with restricted maximum likelihood (REML). Subgroup analyses examined treatment duration (< 2 weeks vs. > 2 weeks) and surgery type. Heterogeneity was assessed with I^2, and stability of outcomes was assessed using leave-one-out (LOO) analyses.</p><p><strong>Results: </strong>Twelve RCTs encompassing 5637 participants were included. Colchicine significantly reduced POAF incidence compared with control (RR = 0.73; 95% CI = 0.64-0.84; <i>p</i> < 0.0001; I² = 0%). Both short-course (< 2 weeks) and long-course (> 2 weeks) regimens were effective without any significant subgroup difference (<i>p</i> = 0.57). Colchicine increased gastrointestinal adverse events (OR = 2.25; 95% CI = 1.86-2.73) and diarrhea (RR = 3.16; 95% CI = 2.25-4.42) but showed no excess bleeding (RR = 0.89; 95% CI = 0.61-1.28), sepsis (RR = 1.32; 95% CI = 0.48-3.59), or in-hospital mortality (RR = 0.90; 95% CI = 0.43-1.86). Funnel plots and Egger's tests revealed no publication bias.</p><p><strong>Conclusions: </strong>Colchicine achieved significant POAF risk reduction without serious adverse events. Both short- and long-course regimens were effective, with the short-course approach offering optimal tolerability. These findings support colchicine as a safe, inexpensive adjunct for POAF prevention.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"1851955"},"PeriodicalIF":2.1,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13273520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Narrative Review of Risk Assessment Approaches for Implantable Defibrillator Therapy to Prevent Sudden Cardiac Death in Acute Myocardial Infarction.","authors":"Nasim Kakavand, Yasaman Shojaei, Mohammadamin Sadri, Sina Rouhani, Razieh Hassannejad, Hamidreza Roohafza, Masoumeh Sadeghi","doi":"10.1155/crp/1981993","DOIUrl":"10.1155/crp/1981993","url":null,"abstract":"<p><p>Despite considerable progress in managing ST-elevation myocardial infarction (STEMI), sudden cardiac death (SCD) remains a major clinical challenge. Although implantable cardioverter-defibrillator (ICD) therapy, guided primarily by left ventricular ejection fraction (LVEF), has been proven to reduce mortality in landmark trials (e.g., MADIT, MUSTT, and MADIT-II), the modest sensitivity and specificity of LVEF limit its utility as a sole risk stratifier. Emerging clinical trends highlight the progression from traditional LVEF-based models to more comprehensive risk assessment strategies. This review critically examines additional modalities, including advanced cardiac magnetic resonance imaging, echocardiography, myocardial biomarkers, detailed electrocardiographic parameters, and assessments of myocardial tissue heterogeneity, as well as patient-specific factors such as age, sex, and prehospital cardiac arrest history. Furthermore, we discuss recent advances, particularly the integration of artificial intelligence and machine learning algorithms, that help to enhance risk prediction and optimize ICD therapy decisions. By combining these novel approaches into a comprehensive risk assessment framework, our review promotes a more personalized strategy to identify STEMI patients most likely to benefit from ICD implantation, improve survival outcomes, and reduce unnecessary interventions. Future research should focus on validating these integrative models in large prospective cohorts and refining current guidelines for ICD therapy post-STEMI.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"1981993"},"PeriodicalIF":2.1,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Ascending Aortic Dilation and Analysis of Influencing Factors in Bicuspid Aortic Valve Patients Using an Explainable Machine Learning Model.","authors":"Sijing He, Ning Yan, Guixuan Nie, Fang Wang, Xingyue Yang, Lili Wang, Lisha Na","doi":"10.1155/crp/9933498","DOIUrl":"10.1155/crp/9933498","url":null,"abstract":"<p><strong>Objective: </strong>Developing a machine learning (ML) model to predict the risk of ascending aortic dilation in patients with a bicuspid aortic valve (BAV). Using SHapley Additive exPlanations (SHAP) to interpret and visualize the model.</p><p><strong>Methods: </strong>This study enrolled 102 BAV patients, who were divided into two subgroups based on ascending aorta diameter (dilated and nondilated). All participants underwent routine echocardiography, clinical baseline data collection, and measurement of plasma matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). Feature selection was performed using univariate analysis followed by the least absolute shrinkage and selection operator (LASSO)-logistic regression (LR) method. Five common ML prediction models were developed: support vector machine (SVM), LR, gradient-boosting machine (GBM), neural network (NNET), and Naïve Bayes (NB) classifier. To identify the best-performing predictive model for ascending aortic dilation in BAV patients, an evaluation of predictive efficacy was carried out by employing ROC curves, calibration curves, and DCA curves. Finally, the optimal model's predictions were interpreted using SHAP.</p><p><strong>Results: </strong>Random allocation of the entire patient population resulted in a training set (<i>n</i> = 72) and a test set (<i>n</i> = 30). Application of LASSO-LR analysis revealed age, plasma MMP-2, and peak aortic valve velocity (Vmax AV) as independent factors influencing ascending aortic dilation in BAV patients. These predictors were integrated into the subsequent ML model. GBM model achieved the optimal overall performance after 5-fold cross-validation. It attained an AUC of 0.982 on the training set, alongside an AUC of 0.915 on the test set. Calibration curves and DCA curves further demonstrate that the model exhibits good calibration and clinical net benefit. According to SHAP analysis, elevated plasma MMP-2 contributed the most to the GBM model's predictions, followed by increased age and elevated Vmax AV.</p><p><strong>Conclusions: </strong>The GBM model offers a valuable tool for predicting ascending aortic dilation in BAV patients. Moreover, SHAP analysis enhances the model's utility by providing clear, actionable insights for clinical management.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"9933498"},"PeriodicalIF":2.1,"publicationDate":"2026-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Obesity Indices and Heart Rate Variability: A Cross-Sectional Study in Asian Young College Students.","authors":"Jun Wang, Xuechun Ding, Juan Wang, Juan Wu, Dongdong Zhu, Juxia Chen, Zhixiang Peng","doi":"10.1155/crp/5718188","DOIUrl":"10.1155/crp/5718188","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the associations of various traditional and novel obesity indices with heart rate variability (HRV) in Asian young college students, assessing their relative importance and potential sex differences.</p><p><strong>Methods: </strong>In this cross-sectional study of 3180 Asian young college students (mean age 19.6 years), we measured eight obesity indices including body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR), and body fat percentage (BFP). HRV was assessed from a 5-min resting electrocardiogram and analyzed across three autonomic domains derived from principal component analysis. We employed sex-stratified linear models followed by a multimodel approach (best subset selection, relative importance analysis, and elastic net regression) to control for collinearity. All analyses were adjusted for age, heart rate, physical activity, and measurement time.</p><p><strong>Results: </strong>BFP demonstrated the strongest associations with HRV parameters, showing significant negative correlation with SDNN (<i>β</i> = -1.76) and positive correlations with LF/HF (<i>β</i> = 0.123) and LFnorm (<i>β</i> = 1.84) (all FDR <i>p</i> < 0.001). Relative importance analysis showed that BFP contributed most to predicting LF/HF (38.1%), significantly exceeding WC (17.5%) and BMI (13.9%). The addition of BMI to BFP was associated with improved prediction for LF/HF and LFnorm (Δ<i>R</i> ² > 0.03). Subgroup analysis showed that overweight/obese individuals with elevated BFP had significantly impaired HRV across all indices, while those with normal BFP showed reduced SDNN only. ROC analysis gave a BFP cutoff of 27.3% for identifying low HRV risk. No significant sex interactions were observed.</p><p><strong>Conclusion: </strong>BFP was identified as the primary obesity indicator for autonomic function assessment in Asian young college students, while traditional indices (BMI, WC) provide valuable incremental information. Integrating body composition measurement into youth cardiovascular risk screening is recommended.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"5718188"},"PeriodicalIF":2.1,"publicationDate":"2026-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetocardiography Combined With the SYNTAX Score for Exploratory Modeling of Clinician-Selected Revascularization Category in Three-Vessel Coronary Artery Disease: A Single-Center Pilot Study.","authors":"Ziyu An, Shipan Wang, Min Zhang, Mingduo Zhang, Feng Xu, Lanxin Feng, Zhao Ma, Huan Zhang, Shuwen Yang, Chenchen Tu, Xiantao Song, Hongjia Zhang","doi":"10.1155/crp/9497660","DOIUrl":"10.1155/crp/9497660","url":null,"abstract":"<p><strong>Background: </strong>Three-vessel coronary artery disease (3V-CAD) often requires revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The SYNTAX score is widely used for anatomical risk stratification, but whether magnetocardiography (MCG) provides incremental information beyond anatomical assessment remains uncertain.</p><p><strong>Objectives: </strong>To evaluate, in an exploratory pilot analysis, whether MCG-derived parameters add information beyond the SYNTAX score for modeling clinician-selected revascularization category in 3V-CAD and to examine the noncausal association between model-treatment concordance and major adverse cardiovascular and cerebrovascular events (MACCEs).</p><p><strong>Methods: </strong>Prospective cohort data were analyzed retrospectively. Candidate MCG parameters were screened using Pearson correlation, random forest analysis, and stepwise logistic regression, and selected variables were combined with the SYNTAX score. Model discrimination, calibration, bootstrap internal validation, and LASSO penalized logistic regression sensitivity analysis were assessed. Model-treatment concordance was explored using Kaplan-Meier analysis and multivariable Cox regression.</p><p><strong>Results: </strong>Among 544 patients, 543 complete cases were available for model evaluation, including 42 CABG events. In the overall cohort, the combined MCG-SYNTAX model did not materially improve discrimination compared with the SYNTAX-only model (AUC, 0.853 vs. 0.847; <i>p</i> = 0.628). Discrimination was also similar in the low-risk subgroup (SYNTAX < 22; AUC, 0.824 vs. 0.848; <i>p</i> = 0.540). In the intermediate-high-risk subgroup (SYNTAX ≥ 22), the combined model had a numerically higher apparent AUC, but this finding was considered hypothesis-generating. Bootstrap internal validation did not support a maintained incremental value of the combined model (optimism-corrected AUC, 0.834 vs. 0.848 for the SYNTAX-only model). In LASSO sensitivity analysis using all appended MCG-derived candidate variables, only the SYNTAX score was retained. The exploratory follow-up analysis showed an unadjusted difference in MACCE-free survival between concordance groups, but this association was not retained after multivariable adjustment and was not interpreted causally.</p><p><strong>Conclusions: </strong>In this single-center pilot modeling study, selected MCG parameters showed limited and unstable incremental value beyond the SYNTAX score for modeling clinician-selected revascularization category in 3V-CAD. These findings do not support clinical implementation at this stage and require external validation. <b>Trial Registration:</b> Chinese Clinical Trial Registry: ChiCTR2200066942.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"9497660"},"PeriodicalIF":2.1,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Enhanced Electrocardiography for the Diagnosis of Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","authors":"Cian P Murray, Hugo C Temperley, Rob S Doyle, Abdullahi Khair, Patrick Devitt, Solomon Asgedom","doi":"10.1155/crp/4994662","DOIUrl":"10.1155/crp/4994662","url":null,"abstract":"<p><strong>Background: </strong>Accounting for approximately 50% of heart failure, heart failure with preserved ejection fraction (HFpEF) is becoming increasingly common as populations age and multimorbidity grows. Diagnosis remains challenging, requiring multimodal testing with echocardiography, biomarkers and sometimes invasive haemodynamics. Artificial intelligence applied to the electrocardiogram (AI-ECG) offers a low-cost, scalable means of detecting HFpEF by extracting patterns beyond human interpretation.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis in accordance with PRISMA, registered prospectively with PROSPERO. PubMed, Embase, Web of Science, and IEEE Xplore were searched to 1 August 2025 for studies evaluating AI/ML models applied to ECGs for the diagnosis of HFpEF or left ventricular diastolic dysfunction (LVDD). Eligible studies reported diagnostic performance compared with a recognized reference standard. Risk of bias was assessed with QUADAS-AI. AUROC values were pooled using a logit transformation and random-effects model, with results back-transformed for interpretability.</p><p><strong>Results: </strong>Ten studies (2021-2025) met inclusion criteria, encompassing > 270,000 participants across diverse populations. Seven studies provided sufficient data for pooling, contributing 11 independent cohorts. The pooled AUROC was 0.84 (95% CI 0.78-0.88), indicating good discriminatory ability, though heterogeneity was extreme (I² = 100%). Three additional studies reported diagnostic metrics without AUROC variance and were synthesized narratively. Risk of bias was moderate to high in several domains, driven by selective cohorts, inconsistent reference standards, and incomplete reporting.</p><p><strong>Conclusions: </strong>AI-ECG shows promise for the detection of HFpEF, but the current evidence base is predominantly retrospective, methodologically heterogeneous, and limited by variable reference standards and insufficient external validation. No prospective, outcome-based studies have yet established its clinical utility, and real-world implementation remains untested.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"4994662"},"PeriodicalIF":2.1,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13238258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148197299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest Management of Cardiac Sarcoidosis: A Comprehensive Review.","authors":"Dunia Alhareth, Alaaeddine El Ghazawi, Sara Ajami, Zyad Saifi, Marwan Refaat","doi":"10.1155/crp/4913082","DOIUrl":"10.1155/crp/4913082","url":null,"abstract":"<p><p>Cardiac sarcoidosis (CS) is a rare but serious manifestation of sarcoidosis. Its complications might include high-grade conduction blocks, atrial and ventricular arrhythmias, and even heart failure. Despite its clinical significance, it exhibits a heterogeneous presentation that makes its diagnosis and management challenging. In this review, we aim to address the different management options of CS, encompassing pharmacotherapy, implantable devices, lifestyle modifications, and surgical interventions. Research findings suggested a positive role of corticosteroids in alleviating the inflammation associated with CS while also improving cardiac parameters. However, given their serious side effects, the use of steroid-sparing medications was also supported. In addition, device-based interventions and ablation were effective in managing the increased risk of arrhythmias and heart failure-associated CS. The importance of lifestyle modifications was tackled as a simultaneous treatment option along with the above. Still, interindividual variability and the absence of strict guidelines were major challenges.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"4913082"},"PeriodicalIF":2.1,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13295146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-17, Interleukin-18, T Regulatory Cells, and T-Helper 17 (Th17) Cells Play a Role in Heart Failure: A Systematic Review and Meta-Analysis.","authors":"Sohat Sharma, Jayant Seth, Cameron J Leong, Simon W Rabkin","doi":"10.1155/crp/5979003","DOIUrl":"10.1155/crp/5979003","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to assess whether interleukin-17 or 18 (IL-17 or IL-18), regulatory T cells (Tregs), and T helper17 (Th17) serum concentrations were different in chronic heart failure not associated with myocarditis compared to healthy individuals.</p><p><strong>Methods: </strong>We searched MEDLINE and Embase for studies with data on IL-17 or IL-18 serum concentrations in patients with chronic heart failure. Forest plots were used to quantify results and depict the standard difference of means, 95% confidence interval (CI), and <i>p</i> value. Continuous outcomes were assessed as weighted mean differences (WMD) with their 95% CI.</p><p><strong>Results: </strong>IL-17 was significantly (<i>p</i> < 0.05) higher in patients with heart failure. The combined effect size under the random effects model (MD = 40.00 pg/mL, 95% CI [6.04, 73.96], <i>p</i> < 0.001) showed a significant overall increase in IL-17 serum levels in heart failure. Th17 was significantly (<i>p</i> < 0.05) higher in patients with heart failure, and Tregs are significantly lower compared to persons without heart failure. The random effects model indicates an MD of 1.59 pg/mL (95% CI [0.88, 2.30]), highlighting significant elevation of TH17 levels in heart failure. For Tregs, the random effects model presented an MD of -2.96 pg/mL (95% CI [-4.52, -1.40]), both indicating a significant decrease in Treg levels in HF. Additionally, serum IL-17 concentrations correlated with the severity of the reduction in LV ejection fraction. For IL-18, all (five) studies reported a statistically significant increase in IL-18 levels in HF. The pooled mean difference was 251.59 pg/mL (95% CI: 177.24-325.93 pg/mL) with a random effects model.</p><p><strong>Conclusion: </strong>Serum IL-17, IL-18 Th17, and Treg count have utility for risk stratification for patients with heart failure, as biomarkers for heart failure severity and potential target pathways for treatment.</p>","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"5979003"},"PeriodicalIF":2.1,"publicationDate":"2026-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13199857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148026655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}